GAITHERSBURG, Md., April 13, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that four poster presentations and one podium presentation highlighting the clinical merits of the Company's AutoloGel™ System in wound management will be presented at the 24th Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) taking place at the Gaylord Texan Hotel and Convention Center in Dallas, Texas from April 14 to 17, 2011.
The AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel, is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.
The following oral abstract highlighting Cytomedix's PRP technology will be presented at SAWC/WHS Oral Abstract Sessions on Saturday, April 16, 2011 from 3:30 p.m. to 4:30 p.m.
- Presented by Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services at Cytomedix, Inc. Session 40.2
The SAWC/WHS Poster Session will be on Friday, April 15, 2011 from 7:30 a.m. to 9:00 a.m. Poster presenters will be available at this time. Posters can be viewed on Friday, April 15th and Saturday, April 16th from 7:30 a.m. until 6:00 p.m. The following posters highlighting Cytomedix's PRP technology will be presented at SAWC/WHS.
- Presented by Jean DeLeon, M.D., Medical Director, Baylor Specialty Hospital, Dallas, TX. Poster Number CS-012
- Presented by Denise Fuston, LPN, Tucson, AZ, Janice Wilson, RN, BSN, CWOCN, Asheville Specialty Hospital, Wound Care Coordinator, and Karl Branch, RN, Asheville Specialty Hospital, Wound Care, Asheville, NC. Poster Number CS-024
- Presented by Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services and Laurie M. Rappl, PT, DPT, CSW, Clinical Development Liaison at Cytomedix, Inc. Poster Number CR-016
- Presented by Janice Wilson, RN, BSN, CWOCN, Asheville Specialty Hospital, Wound Care Coordinator, and Karl Branch, RN, Asheville Specialty Hospital, Wound Care, Asheville, NC. Poster Number CR-048
"The five clinical studies presented at this year's SAWC reflect the efforts of many practitioners, both independent clinicians and our internal clinical team, and underscore the clinical utility of AutoloGel to rapidly and effectively improve healing in a variety of wound management indications," noted Martin P. Rosendale, Chief Executive Officer of Cytomedix. "The growing body of clinical evidence and health economic outcomes should continue to drive clinical adoption of the AutoloGel System to treat chronic and recalcitrant wounds which remain a large and unmet medical need despite the billions of dollars spent on wound management."
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112), which has shown promise in preclinical testing. Additional information regarding Cytomedix is available at .
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Cytomedix, Inc. David Jorden, Executive Board Member Martin Rosendale, CEO Andrew Maslan, CFO (240) 499-2680 Lippert/Heilshorn & Associates Anne Marie Fields (email@example.com) (212) 838-3777 Bruce Voss (firstname.lastname@example.org) (310) 691-7100